“we’re on the cusp of a change,” says dr. anmol kapoor. “and we’ve got to decide how we want health care to be provided — reactively or proactively.”
dr. kapoor, cardiologist and ceo of bioaro, a canadian biotech company, believes a significant flaw of the current health-care system is that it’s reactive. “a patient must present with symptoms before anything is looked into,” he explains. “the right markers have to be checked for anything to be found. then, their test results have to be suitably abnormal. the best-case scenario is a diagnosis that precedes a string of available treatment options.”
the issue with that approach, dr. kapoor points out, is that many diseases aren’t symptomatic until they’re much more advanced. health-care providers can’t possibly give every patient every test under the sun “just in case,” he says, as resources simply won’t allow it. “we’re not advancing medicine by continuing to take this reactive approach.”
what will advance medicine, says dr. kapoor, is genetic analysis.
while it’s easy to get genetics and genomics mixed up, the two have very different meanings. dr. kapoor explains it using a hockey analogy: “genetics is concerned with looking at and analyzing one or several specific genes, which is akin to following your favourite hockey player through a league. you cheer them on as they rise through ranks: similar to passing on dna from one generation to another.